Showing results (71-80 of 182) with videos related to
Sort By:
Pageof 19
Metabolism: Clinical and Experimental|April 14, 2017
A prospective study of low fasting glucose with cardiovascular disease events and all-cause mortality: The Women's Health InitiativeMorgana Mongraw-Chaffin, Andrea Z LaCroix, Dorothy D Sears, et al.Mayo Clinic Proceedings|August 2, 2024
Effects of Inclisiran in Patients With Atherosclerotic Cardiovascular Disease: A Pooled Analysis of the ORION-10 and ORION-11 Randomized TrialsR Scott Wright, Kausik K Ray, Ulf Landmesser, et al.Diabetes, Obesity & Metabolism|May 17, 2024
Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION-9, ORION-10 and ORION-11 Phase 3 randomized trialsLawrence A Leiter, Frederick J Raal, Gregory G Schwartz, et al.Atherosclerosis|November 28, 2023
Inclisiran in patients with prior myocardial infarction: A post hoc pooled analysis of the ORION-10 and ORION-11 Phase 3 randomised trialsUlf Landmesser, Wolfgang Koenig, Lawrence A Leiter, et al.Circulation Research|February 8, 2014
Mutation in the γ2-subunit of AMP-activated protein kinase stimulates cardiomyocyte proliferation and hypertrophy independent of glycogen storageMaengjo Kim, Roger W Hunter, Lorena Garcia-Menendez, et al.European Journal of Preventive Cardiology|April 17, 2025
Efficacy and safety of inclisiran based on background lipid-lowering treatmentUlf Landmesser, Wolfgang Koenig, Lawrence A Leiter, et al.American Journal of Preventive Cardiology|May 30, 2023
Efficacy and safety of inclisiran in patients with cerebrovascular disease: ORION-9, ORION-10, and ORION-11Wolfgang Koenig, Kausik K Ray, Ulf Landmesser, et al.Cardiovascular Drugs and Therapy|December 22, 2022
Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled TrialsWolfgang Koenig, Lorena Garcia Conde, Ulf Landmesser, et al.American Journal of Physiology. Endocrinology and Metabolism|June 15, 2017
Map4k4 impairs energy metabolism in endothelial cells and promotes insulin resistance in obesityRachel J Roth Flach, Marina T DiStefano, Laura V Danai, et al.Journal of the American Society of Nephrology : JASN|January 28, 2026
Inclisiran in Patients with CKD: Post Hoc Pooled Analysis of Three Phase 3 TrialsUlf Landmesser, Kausik K Ray, Frederick J Raal, et al.Pageof 19